Bimatoprost / working resource
Label and document checklist
Keep product identity, testing documents and regulatory status as separate checks.
Start with the product-specific question
What the label says it is for
Bimatoprost for short or sparse eyelashes, with the evidence and its limits in plain view. What should I know about what the label says bimatoprost is for?
Open the Bimatoprost library ↗In a 2012 randomized trial, subjects were randomized over 5 months to once-daily bimatoprost 0.03% (n = 137) or vehicle (n = 141). A higher percentage of subjects treated with bimatoprost 0.03% (78.1%) than vehicle (18.4%) demonstrated at least a 1-grade increase in global eyelash assessment score at week 16 (P < .0001). The abstract lists the short-term duration of the trial and that black subjects were not enrolled secondary to technical requirements of digital image analysis as limitations.
Read the original record ↗
Keep three different checks separate.
1. Identity
2. Documentation
3. Current status
Turn a missing detail into a specific question.
What should I know about what the label says bimatoprost is for?
What should I know about iris color and eye pressure?
What should I know about compounded and approved bimatoprost?
Documents have different scopes. A batch assay, trial paper, regulatory record and pharmacy label cannot replace one another.
These fields stay in this page until you leave or reload. No notes are saved or transmitted. Print a copy if you want to keep your work. Educational organization tools do not replace clinical advice.